



ALERT

NicOx's Shareholder Meetings

April 9, 2010. Sophia Antipolis, France. www.nicox.com

An ordinary shareholder meeting of NicOx S.A. (NYSE Euronext Paris: COX) followed by an extraordinary shareholder meeting is called on **Wednesday May 19, 2010 at 10:00 am CET** at the Grand Hotel Mercure – 3550 routes des Dolines – BP 105 – 06901 Sophia Antipolis Cedex.

To obtain the documents mentioned in articles R.225-81 and R.225-83 of the French *Code de commerce* please write to the Company's headquarters, Les Taissounières – Bât HB4 – 1681 route des Dolines – BP 313 – 06906 Sophia Antipolis Cedex – France.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Molecular Entities (NME) for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases.

NicOx's lead investigational compound is naproxcinod, an NME and a first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug candidate developed for the relief of the signs and symptoms of osteoarthritis (OA), which is currently under review by regulatory authorities, following the submission and filing of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). The FDA has set an action date of July 24, 2010, under the Prescription Drug User Fee Act (PDUFA).

In addition to naproxcinod, NicOx's pipeline includes several nitric oxide-donating NMEs, which are in development internally and with partners, including Merck & Co., Inc. and Bausch + Lomb, for the treatment of hypertension, cardiometabolic diseases, widespread eye diseases and dermatological disease.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps).

